FDA Approves Lumos Labs' Digital Treatment for ADHD

FDA Clearance for LumosityRx: Lumos Labs has received FDA approval for LumosityRx, a prescription digital therapeutic designed to enhance attention span in adults with ADHD, particularly those aged 22 to 55.

Clinical Trial Results: A pivotal trial demonstrated that users of LumosityRx showed significant improvements in attention compared to a control group, with clinicians rating many participants as "much improved."

Rising ADHD Incidence: A CDC report indicates a growing concern over pediatric ADHD, with diagnoses increasing from 6.1 million in 2016 to 7.1 million in 2022 among children and adolescents in the US.

Market Outlook: GlobalData forecasts a rise in ADHD cases across major markets, predicting an increase in diagnosed cases from 21.1 million in 2022 to 22 million by 2032, driven by improved screening methods.